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Diabetes, Cognitive Decline, and
Mild Cognitive Impairment
Among Diverse Hispanics/




Hispanics/Latinos are the largest ethnic/racial group in the U.S., have the highest 
prevalence of diabetes, and are at increased risk for neurodegenerative disorders. 
Currently, little is known about the relationship between diabetes and cognitive 
decline and disorders among diverse Hispanics/Latinos. The purpose of this study is 
to clarify these relationships in diverse middle-aged and older Hispanics/Latinos.
RESEARCH DESIGN AND METHODS
TheStudy ofLatinos–Investigation of Neurocognitive Aging(SOL-INCA) isanancillary 
study of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). HCHS/
SOL is a multisite (Bronx, NY; Chicago, IL; Miami, FL; and San Diego, CA), probability-
sampled (i.e., representative of targeted populations), and prospective cohort 
study. Between 2016 and 2018, SOL-INCA enrolled diverse Hispanics/Latinos aged 
‡50 years (n 5 6,377). Global cognitive decline and mild cognitive impairment (MCI) 
were the primary outcomes.
RESULTS
Prevalent diabetes at visit 1, but not incident diabetes at visit 2, was associated with 
significantly steeper global cognitive decline (bGC 520.16 [95% CI 20.25; 20.07]; 
P < 0.001), domain-specific cognitive decline, and higher odds of MCI (odds ratio 1.74 
[95% CI 1.34; 2.26]; P < 0.001) compared with no diabetes in age- and sex-adjusted 
models.
CONCLUSIONS
Diabetes was associated with cognitive decline and increased MCI prevalence 
among diverse Hispanics/Latinos, primarily among those with prevalent diabetes at 
visit 1. Our findings suggest that significant cognitive decline and MCI may be 
considered additional disease complications of diabetes among diverse middle-
aged and older Hispanics/Latinos.
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Hispanics/Latinos (henceforth referred to
here as Latinos) are the largest ethnic/
racial group in the U.S. and represent
nearly one-fifth of the population (1).
Latinos have the highest prevalence of
diabetes of any ethnic/racial groupwhen
diagnosed (13.6%) and undiagnosed (6.2%)
cases are included in estimates (2,3). Ad-
ditionally, Latinos have the earliest ageof
diabetes diagnoses of any ethnic/racial
group in the country, provided they have
access to health care (4,5). Similarly, age
of mild cognitive impairment (MCI) and
dementia onset are thought to be ear-
lier among Latinos compared with other
ethnic/racial groups (6,7). However, few
studies have examined cognitive decline
and disorders among middle-aged Lati-
nos when cognitive changes are thought
to begin (8). From age 40 years, diabetes
prevalence rapidly increases each suc-
cessive decade to nearly half (49%) of
Latinos age .70 years, representing a
445% increase (9). The prevalence ofMCI
has an accelerating trajectory per decade
similar to that of diabetes (10), which sug-
gests that diabetes and cognitive impair-
ment may be interrelated among Latinos.
Diabetes is associated with microvas-
cular brain changes and stroke that man-
ifest in cognitive decline and dementia
(11). Behaviorally, diabetes is related to
lower cognitive function but not gener-
ally with significant cognitive decline
(12,13). In previous studies, diabeteswas
associated with increased MCI prevalence
in older Latinos and whites, but the ef-
fects were small and explained by other
cardiovascular disease (CVD) risk factors
(14–16).
In general, previous studies of cogni-
tive aging and disorders have focused on
older adults (i.e., age $75 years) and
have relied on self-reports or medical
records of diabetes diagnosis. Few have
used American Diabetes Association (ADA)
diagnostic criteria for ascertaining dia-
betes. Additionally, there is a dearth of
information about the length of diabetes
exposure in relation to cognitive aging.
Lastly, most studies have focused on
whites and not examined diabetes, cog-
nition, and MCI in other representative
populations in which diabetes is highly
prevalent. In this study of diversemiddle-
aged and older Latinos, we test the rela-
tionships between diabetes and cognitive
decline andMCI and assess whether lon-
ger diabetes exposure affect relationships
between cognitive decline and MCI.
RESEARCH DESIGN AND METHODS
Study Design
The Study of Latinos–Investigation of
Neurocognitive Aging (SOL-INCA) is a His-
panic Community Health Study/Study of
Latinos (HCHS/SOL) ancillary study.HCHS/
SOL and SOL-INCA study designs and ra-
tionales are available elsewhere (17–19).
HCHS/SOL is a multisite, population-
based, probability-sampled, prospective
cohort study of CVD and diabetes among
diverse Latinos (visit 1: 2008–2011). The
complex survey sampling procedures used
in HCHS/SOL were designed to yield rep-
resentative data for diverse Latinos in
four targeted U.S. metropolitan areas:
Bronx, NY; Chicago, IL; Miami, FL; and
SanDiego, CA. Each Field Center enrolled
;4,000 eligible self-identified Latinos
(ages18–74years;N516,415). Biospeci-
mens (e.g., blood) were assayed for CVD
risk factors (e.g., fasting blood glucose)
and stored for later studies.DetailedHCHS/
SOL sampling procedures have previously




visit 1 involved only middle-aged and
older (ages 45–74 years) participants who
were oversampled (n 5 9,714) in the
cohort. TheNeurocognitive ReadingCen-
ter trained and the Field Centers directly
supervised bicultural/bilingual technicians
who administered the brief cognitive bat-
tery, which included four tests: 1) Six-
Item Screener (SIS) (mental status) (20),
2) Brief-Spanish English Verbal Learning
Test (B-SEVLT) (verbal episodic learning
andmemory) (21), 3)Word Fluency (WF)
(22), and 4) Digit Symbol Subtest (DSS)
(processing speed, executive function)
(23). Of all eligible participants, only 59
(,1%) did not participate due to health
limitations and/or refusals. Additional in-
formation about the cognitive tests used
at visit 1 and the cohort has previously
been published (24).
SOL-INCA cognitive tests were admin-
istered to eligible HCHS/SOL participants
who returned for visit 2, which occurred
on average ;7 years after visit 1. We
expanded the cognitive battery to derive
an MCI research diagnosis based on Na-
tional Institute on Aging–Alzheimer’s As-
sociation (NIA-AA)criteria (25). Inaddition
to visit 1 tests, we included the Trail
Making Test (TMT) (parts A and B [exec-
utive function]) and NIH Toolbox Picture
Vocabulary Test (PVT) (general premorbid
cognitive function), self-reported cogni-
tive decline (Everyday Cognition-12 [eCog-
12]), and instrumental activities of daily
living (IADL) (for functional impairment)
(26,27). More detailed information about
the battery of tests has previously been
published (10,19). The PVT was used to
assess premorbid cognitive function, since
these scores remain stable with age and
into later neurodegenerative stages, and
to control for potential educational qual-
ity test biases (28). At HCHS/SOL visit 2,
the Coordinating Center identified 7,420
potentially eligible participants for SOL-
INCA. Inclusion criteria were 1) visit 2 com-
pletion, 2) visit 1 neurocognitive testing
completion, and3) age$50 years. Of this
group, 222 were determined to be in-
eligible (e.g., missing visit 1 data), 569
wereeligible but refused, and6,377were
eligible and agreed to participate. The
overall response rate for SOL-INCA of
eligible participants was 88.7%. Eligible
participants returning for SOL-INCA had
largely similar visit 1 characteristics com-
pared with those in the overall pool of
eligible visit 1 participants (Supplemen-
tary Table 1). Furthermore, to guardagainst
possible biases by sample attrition, the
HCHS/SOL Coordinating Center generated
study-specific calibrated probability weights
that adjust for nonresponse (e.g., deaths)
and allow generalization of estimates to
the HCHS/SOL metropolitan area target
populations aged $50 years.
Cognitive change scores for repeated
cognitive tests were calculated using
regression-based methods, whereas sur-
vey linear regression models were used
to predict cognitive performance at SOL-
INCA as a function of visit 1 cognitive
performance,with adjustment for elapsed
time (in days) between cognitive assess-
ments. Regression-based change score
methods and their application to neuro-
cognitivemeasures have previously been
described (29). Briefly, test-specific stan-
dardized measures of change were sub-
sequently calculated, T22 T2pred/RMSE,
where T2 is the respondent’s cognitive
score at SOL-INCA, T2pred is their pre-
dicted score at visit 2, and RMSE is the
regression-derived root mean squared
error. A global cognitive change measure
was subsequently generated by averag-
ing across the change measures pertain-
ing to each of the cognitive domains (19).
MCI diagnostic criteriawere operation-
alized to generate four core NIA-AA cri-
teria: 1) any cognitive score in the mildly
impaired range, i.e., from 21 to 22 SDs
compared with the SOL-INCA internal ro-
bust norms (age-, education-, sex-, andPVT-
adjusted scores), 2) significant cognitive
decline (greater than or equal to20.055
SD/year) from visit 1, 3) self-reported
cognitive decline, and 4) no or minimum
IADL impairment (25). Cognitive impair-
ment and significant cognitive decline cri-
teria were used to reduce false-positive
bias. Individuals with severe cognitive
impairment (below 22 SD relative to
SOL-INCA robust norms and with significant
functional impairment) were not included
in these MCI prevalence estimates (10).
Diabetes assessment at HCHS/SOL
visit 1 and visit 2 was based on ADA
criteria: FPG$126mg/dL (7mmol/L), 2-h
postload glucose level (2-h oral glucose
tolerance test)$200 mg/dL (11.2 mmol/
L), A1C level $6.5% (48 mmol/mol), or
hypoglycemic agent use (i.e., scanned
medication bottles) (9,30). We gener-
ated three groups, 1) no diabetes, 2)
diabetes at visit 1 and visit 2 (prevalent),
and 3) new incident diabetes at visit
2 (incident), to capture associations be-
tween diabetes exposure and cognitive
decline and MCI.
Covariables were included to account
for confounding and other factors that
could potentially explain associations of
cognitive decline and MCI with diabetes,
including sociocultural and CVD risk fac-
tors. All covariables, with the exception
of age, were measured at visit 1.
Modelcovariables includedLatinoback-
ground (six groups), sex, age in years,
education(,12years,12years,.12years),
language preference (0 5 English, 1 5
Spanish), smokingstatus (05no,15yes),
a dichotomous indicator for alcohol con-
sumption (one or more drinks per day),
self-reported prevalent stroke or tran-
sient ischemic attack (TIA), myocardial
infarction, and BMI based on weight mea-
sured in kilograms and height measured in
centimeters. We also corrected for depres-
sive symptoms (Center for Epidemiologic
Studies Depression Scale-10 [CESD-10]) us-
ing abinary indicator to separate individual
withelevateddepressive symptoms ($10)
fromothers; the cut point for theCESD-10
was based on validation work previously
conducted in HCHS/SOL (31). In addition,
we tested genetic risk for cognitive decline
and MCI in sensitivity analyses with apo-
lipoprotein (apo)E genotype (34 and 44 vs.
other) as a covariable in separatemodels
(described below).
The analytic sample included 6,377
enrolled participants aged 50–86 years
at HCHS/SOL visit 2. For the cognitive
decline analyses, we excluded n 5 120
participants who reported mixed Latino
backgrounds and n 5 14 participants
who did not provide background infor-
mation. For multivariable modeling, we
also excluded n 5 150 individuals with
missing values on any of the covariates
of interest. The analytic sample size was
n 5 6,093. For the MCI analyses, we
additionally excluded n 5 91 partici-
pants who were missing cognitive data
needed to classifyMCI.We also excluded
n5 80 participants who met criteria for
suspected severe cognitive impairment
(,2 SD below the normative mean on
any cognitive domain and functional im-
pairment). Excluded participants had
similar age, sex, and Latino background
distributions relative to those included
in the analytic sample.
In sensitivity analyses, we additionally
adjusted (see list of included covariables
above) for apoE4 genotype. These anal-
yses focused on participants who con-
sented for genetic data analyses. The
analytic samples for thesemodels included
n 5 4,141 participants. Compared with
those consenting for genetic testing, non-
consenting participants were more likely
to be male (40.8% vs. 47.2%; P5 0.001)
and have,12 years of education (36.3%
vs. 41.7%; P , 0.001). Age (P 5 0.107)
and diabetes status (P 5 0.955) did not
substantively differ between consenters
and nonconsenters.
Statistical Analyses
First, we provide descriptive statistics to
characterize the target population over-
all and by diabetes status (Table 1). Sec-
ond,we describe and test the differences
in means for the cognitive measures at
visit 1 and at SOL-INCA for each of the
cognitive domains as well as global cog-
nition.Weused survey-adjusted t tests to
examine crudeandage- and sex-adjusted
mean differences between incident and
prevalent diabetes, separately, versus no
diabetes. For each test, we compare the
crude and adjusted cognitive scores for
no diabetes with those for 1) incident
diabetes and 2) prevalent diabetes. These
estimates are included in Supplementary
Table 2. Third, we use survey linear regres-
sion models to test 1) crude, 2) age- and
sex-adjusted, and 3) covariable-adjusted
associations between diabetes (reference:
no diabetes) and global cognition as well
as domain-specific cognitive change. The
b-coefficients and SEs derived from the
age- and sex-adjusted and fully adjusted
estimatedmodelsarepresented inTable2.
Fourth, we use survey logistic regression
to model prevalent MCI as a function of
diabetes status. As with the above, we fit
1) crude, 2) age- and sex-adjusted, and 3)
covariable-adjusted models. The estimated
odds ratios (ORs) and 95%CIs from the age-
and sex-adjusted and fully adjusted models
are also presented in Table 2. For all the
tested models, we calculated and plotted
post hoc estimates of crude, age- and sex-
adjusted, and full covariables–adjusted
marginal means (for the continuous
change measures [Fig. 1]) and probabil-
ities (for prevalent MCI [Fig. 2]) and their
95% CIs. These plots facilitate visualization
of associations between diabetes and
the cognitive outcomes, in addition to
showcasing the attenuations in estimated
means and probabilities in each of the
considered diabetes groups as a result of
covariable adjustments in the models.
In sensitivity analyses, we further ad-
just the estimatedmodels for apoE4. The
estimates derived from the survey linear
regression (for cognitive change) and sur-
vey logistic regression model (for MCI) are
presented in Supplementary Figs. 1 and 2,
respectively.
Ethics Committee Approval
The HCHS/SOL and the SOL-INCA studies
were reviewed and approved by the insti-
tutional review boards of the University
of California, San Diego, and all partici-
pating sites.
RESULTS
The target population characteristics
and covariables of interest are shown in
Table 1 both for the overall sample and by
diabetes status. More than a quarter
(28.5%) of people with diabetes were
identified at visit 1 (prevalent diabetes),
and 1 in 10 participants met criteria for
incident diabetes (10.4%) at visit 2. For
visit 2, mean 6 SD age was 63.4 6 8.2
years and 55% of subjects were females,
39.7% had ,12 years’ education, and
88.0% identified Spanish as their pre-
ferred language. Close to one-half met
criteria for hypertension (47.0%) and 3.5%
reported a prevalent stroke/TIA and 3.1%
a myocardial infarction. Finally, 31.0%
met CESD-10 criteria for elevated depres-
sive symptoms.
Theprevalent diabetesgroupwasolder
(66.1 vs. 62.2 years old for no diabetes)
and more likely to have ,12 years of
education (47.1% vs. 34.8% for no dia-
betes). Theprevalent diabetes groupwas
more likely to be hypertensive (66.0% vs.
37.0% for no diabetes), close to three
times as likely to have had a stroke/TIA
(6.6% vs. 2.3% for no diabetes), and 2.5
times more likely to have had a myocar-
dial infarction (5.0% vs. 2.1% for no dia-
betes).With theexceptionofhigher levels
of hypertension (53.3% vs. 37.0%), the
incident diabetes group had largely sim-
ilar profiles for the considered character-
istics compared with the no diabetes
group. Finally, both prevalent (31.5 kg/m2)
and incident (31.3 kg/m2) diabetes
groups had higher average BMI relative
to the no diabetes group (28.7 kg/m2).
The prevalent diabetes group had con-
sistently lower visit 1 and visit 2 (average
7 years later) scores on all considered
cognitive tests (Supplementary Table 2).
The incident diabetes groupdidnot differ
in their cognitive performance at visit 1
and visit 2 relative to the no diabetes
group. In age- and sex-adjusted models for
cognitive change (Table 2), the prevalent
diabetes group had more pronounced
levels of decline (z score units) compared
with no diabetes for global cognition
(bGC 5 20.16 [95% CI 20.25; 20.07];
P , 0.001), as well as each of the consid-
ered cognitive domains, including episodic
memory (bB-SEVLT-Sum20.10 [95% CI20.19;
20.01]; P , 0.05), learning (bB-SEVLT-Recall
20.09 [95% CI 20.17; 20.01]; P , 0.05),
verbalfluency (bWF20.16 [95%CI20.25;
20.06]; P , 0.01), and processing
speed (bDSS 20.20 [95% CI 20.29;
20.10]; P , 0.001). Incident diabetes
was not significantly associated with any
of the cognitive measures.
The associations between prevalent di-
abetes and episodic learning and mem-
ory were explained by adjustments for
the model covariables. The inverse associa-
tions between prevalent diabetes and global
cognition (bGC20.12 [95%CI20.20;20.03];
P,0.01), verbalfluency (bWF20.11 [95%CI
20.20; 20.02]; P , 0.05), and processing
speed (bDSS 20.14 [95% CI 20.24; 20.05];
P, 0.01) were attenuated but remained
statistically significant after covariable
adjustments (Table 2 and Fig. 1).
In age- and sex-adjusted models,
prevalent diabetes increased the ORs
for MCI relative to no diabetes by 74%
(OR 1.74 [95% CI 1.34; 2.26]; P, 0.001).
The higher ORs for MCI among the
prevalent diabetes group were attenu-
ated (OR 1.48 [95% CI 1.13; 1.94]; P ,
0.01) but not explained by adjustments to
the model covariables (Table 2 and Fig. 2).
These results remained consistent in sensi-
tivity analyses following adjustment to
apoE4 status (Supplementary Figs. 1 and 2).
CONCLUSIONS
Diabeteswas associatedwith significantly
lower cognitive function and increased
cognitivedecline andMCIprevalence com-
pared with Latinos without diabetes. Spe-
cifically, participants with diabetes at
visit 1 evinced significant7-year cognitive
decline. Secondly, prevalent diabetes was
associated with a marked increase in MCI
prevalence. In coming decades, the Latino
older adult population is projected to
quadruple and have the largest increase
in ADRD prevalence of any U.S. ethnic/
racial group (32,33). Additionally, Latinos
also have the earliest age of diabetes
diagnosis and the highest rates of un-
controlled diabetes of all ethnic/racial
groups in the U.S. (3,4). Therefore, preventing
Table 1—Descriptive statistics to characterize the population of SOL-INCA overall and by diabetes status
No diabetes Incident diabetes Prevalent diabetes Overall P
Unweighted n 3,760 649 1,684 6,093
Age, years, mean (SD) 62.2 (8.0) 63.2 (8.0) 66.1 (8.3) 63.4 (8.3) ,0.001
Female, % 55.1 49.2 55.3 54.5 0.169
Education, years, %
,12 34.8 38.7 47.1 38.7 ,0.001
12 21.5 24.1 21 21.6
.12 43.7 37.2 31.9 39.7
Spanish language preference, % 87.6 88.4 88.5 88 0.764
Latino background, %
Dominican 9.8 9.3 10 9.8 0.051
Central American 7.8 5.4 7.8 7.5
Cuban 27.1 29.2 25.6 26.9
Mexican 34.4 35.3 34.1 34.4
Puerto Rican 14.7 16.4 18.8 16
South American 6.2 4.4 3.8 5.3
Hypertension, % 37 53.3 66 47 ,0.001
Prevalent stroke/TIA, % 2.3 2.3 6.6 3.5 ,0.001
Myocardial infarction, % 2.1 3.9 5 3.1 ,0.001
CESD-10 ($10), % 28.7 33.4 35.1 31 0.002
Current smoker, % 20.4 18.6 14.1 18.4 ,0.001
More than one alcoholic drink daily, % 11 11.6 7.3 10 0.007
BMI, kg/m2, mean (SD) 28.7 (5.1) 31.3 (5.4) 31.5 (5.8) 29.7 (5.5) ,0.001
Metabolic syndrome, % 38.3 70.8 80.7 53.8 ,0.001
A1C, mmol/mol, mean (SD) 37.3 (3.7) 40.4 (3.6) 57.9 (20.2) 43.5 (14.7) ,0.001
Prevalent diabetes since visit 1 and incident diabetes at visit 2. P values are based on survey-adjusted x2 tests for categorical measures and t tests for
continuousmeasures.With the exception of age (in years), all other characteristics weremeasured at visit 1. Lowmental status at visit 1 and visit 2 was
measured as having a score #4 in the SIS.
diabetes, early detection, and improving
and increasing glycemic control for Lati-
nos with diabetes are vital priorities for
potentially mitigating diabetes complica-
tions, including reducing the risk of cog-
nitive decline and impairment.
Previous studies of diabetes, cognitive
decline, and MCI have reported mixed
results. Among whites in Olmstead County,
MN, diabetes was marginally associated
with prevalent MCI but only when prev-
alent diabetes and complications were
also considered (34). In the same cohort,
MCI incidence was associated with longer
diabetes exposures (16). Among middle-
aged and older Mexican-origin Latinos
and whites in a cross-sectional, mixed
community-based rural and urban (i.e.,
dementia registry) Texas study, diabetes
was not related toMCI prevalence (6). In
another study of mostly older Mexican-
origin Latinos, diabetes was associated
with faster decline inmental status scores
and higher mortality compared with no
diabetes. The authors cautioned that ig-
noringmortality in analyses could lead to
underestimates of associations between
diabetes and cognitive decline (13). Among
older Caribbean Latinos, diabetes was
marginally associated with MCI, which
was explained by competing CVD risks
(14). In the same sample, diabetes was
associated with lower cognitive perfor-
mance but not cognitive decline (8). How-
ever, among middle-aged Caribbean
Latinos, higher A1C values were associ-
ated with lower cognitive performance
(35). In a study of older Germans, di-
abetes was not significantly related to
MCI. In that study, the authors reported
small (nonsignificant) associations be-
tween diabetes and psychomotor speed
and cognitive flexibility (15). There are
several explanations for the differences
in findings between the aforementioned
studies and SOL-INCA findings. Firstly,
SOL-INCA is a much larger and younger
cohort in which diabetes was rigorously
ascertainedperADAguidelines. Secondly,
we assessed both cognitive function and
diabetes in midlife, whereas most pre-
vious studies retrospectively determined
midlife diabetes status via self-report or
medical records in relation to later-life
cognitive function. Thirdly and perhaps
most importantly, diabetes prevalence
washigher inLatinoscomparedwithother
cohort studies of whites. Thus, our find-
ings are consistent with previous studies
that demonstrated that diabetes is as-
sociated with lower cognitive function
among older Latinos. Moreover, middle
age appears to be a particularly vulner-
able developmental period for Latinos
with diabetes for cognitive decline and
MCI. Finally, our study and other studies




No diabetes 0.00 (0.00; 0.00) 0.00 (0.00; 0.00)
Incident 0.06 (20.06; 0.18) 0.07 (20.05; 0.19)
Prevalent 20.16 (20.25; 20.07)*** 20.12 (20.20; 20.03)**
DB-SEVLT-Sum
No diabetes 0.00 (0.00; 0.00) 0.00 (0.00; 0.00)
Incident 0.12 (20.01; 0.25) 0.13 (0.00; 0.26)*
Prevalent 20.10 (20.19; 20.01)* 20.05 (20.14; 0.03)
B-SEVLT-Recall
No diabetes 0.00 (0.00; 0.00) 0.00 (0.00; 0.00)
Incident 0.05 (20.06; 0.17) 0.05 (20.07; 0.16)
Prevalent 20.09 (20.17; 20.01)* 20.06 (20.15; 0.02)
DWF
No diabetes 0.00 (0.00; 0.00) 0.00 (0.00; 0.00)
Incident 20.01 (20.12; 0.10) 0.01 (20.10; 0.13)
Prevalent 20.16 (20.25; 20.06)** 20.11 (20.20; 20.02)*
DDSS
No diabetes 0.00 (0.00; 0.00) 0.00 (0.00; 0.00)
Incident 20.02 (20.13; 0.10) 0.01 (20.10; 0.13)
Prevalent 20.20 (20.29; 20.10)*** 20.14 (20.24; 20.04)**
Prevalent MCI at visit 2
No diabetes 1.00 (1.00; 1.00) 1.00 (1.00; 1.00)
Incident 1.20 (0.73; 1.98) 1.10 (0.66; 1.84)
Prevalent 1.74 (1.34; 2.26)*** 1.48 (1.13; 1.94)**
Data are b (95% CI) except for data for prevalent MCI at visit 2, which are OR (95% CI). Change
estimatesarebasedon survey linear regressionmodels.MCI estimates arebasedon survey logistic
regression models. Prevalent diabetes, since visit 1; incident diabetes, at visit 2. M1: model
adjusted for age and sex. M2: model fully adjusted, including adjustment for Latino background
(six groups), sex, age, education (,12 years, 12 years,.12 years), language preference (Spanish,
English), whether someone is a current smoker (0 5 no, 1 5 yes), a dichotomous indicator
for alcohol consumption (one or more drinks per day), self-reported prevalent stroke or TIA,
myocardial infarction, BMI based on weight measured in kilograms and height measured in
centimeters, and $10 on CESD-10. With the exception of age, all covariates were measured
at visit 1. ***P , 0.001; **P , 0.01; *P , 0.05.
Figure 1—Estimates of crude and adjusted marginal means (and their 95% CIs) of cognitive change.
Results are derived from survey linear regression estimates. Prevalent diabetes, since visit 1;
incident diabetes, at visit 2. Adjusted models correct for Latino background (six groups), sex, age,
education (,12 years, 12 years, .12 years), language preference (English, Spanish), whether
someone is a current smoker (05 no, 15 yes), a dichotomous indicator for alcohol consumption
(one or more drinks per day), self-reported prevalent stroke or TIA, myocardial infarction, BMI
based on weight measured in kilograms and height measured in centimeters, and $10 on CESD-10.
With the exception of age, all covariates were measured at baseline.
suggest that the magnitude of the prob-
lem of diabetes for Latinos regarding brain
function and disease may be higher com-
pared with other populations.
In this Latino cohort study, there were
other notable correlates that explained
some of the associations between dia-
betes, cognitive decline, and MCI. Older
age, male sex, and smoking were also
significantly associated with significant
cognitive decline in most domains. Men
with diabetes evinced more decline in
verbal learning and memory, a hallmark
ofAlzheimerdisease, thanwomen.Higher
education was generally protective of
cognitive decline in all domains. For MCI,
older age and hypertension were asso-
ciated with increased MCI prevalence,
whereas having more years of education
was related to decreasedMCI prevalence.
Interestingly, althoughmenshowedgreater
cognitive decline than women, the prev-
alence of MCI was indistinguishable be-
tween the sexes. This finding suggests
thatmenmay report, or have, fewer sub-
jective complaints of cognitive decline
and functional impairment comparedwith
women, which are both key components
of the MCI diagnosis.
There are several strengths and weak-
nesses that readersmaywish to consider
in evaluating the results of this study.
SOL-INCA is the largest study of diabetes,
cognitive decline, and MCI, which im-
proved our statistical power to detect
meaningful associations. The effect sizes
of statistical associations in this studywere
modest. However, given the representa-
tiveness of this sample, the population-
level public health benefits would likely
be large. Secondly, diabetes is all too com-
mon and poorly controlled in this cohort
of diverse Latinos, which also amplified
statistical power to detect effects (3).
Thirdly, the ADA guidelines–concordant
diabetes diagnostic approach used in
HCHS/SOLandSOL-INCA ismore rigorous
thanused in previous studies of cognitive
function andMCI.Our study is somewhat
limited by our brief cognitive assessment
battery and our reliance on participant
self-reported subjective cognitive decline
and functional decline (e.g., handling a
checkbook). Although inclusion of infor-
mant reports of cognitive and functional
limitations is optional in NIA-AA criteria,
SOL-INCA did not include informant re-
ports of cognitive and functional limita-
tions, which could have improved MCI
case identifications. Secondly, we did not
fully account for mortality in this study
(n5 405 deaths between visit 1 and visit
2). Instead, deathswere accounted for as
nonresponses in our sampling weights.
This may have resulted in a small under-
estimation of the effect of diabetes on
cognitive decline andMCI (13). Thirdly, it
is possible thatparticipantswithdiabetes
in this studymay have had poor cognitive
functioning prior to developing diabetes.
Given our study design, our operational
definition of diabetes following ADA cri-
teria, and the high rates of undiagnosed
diabetes among Latinos (3), we were un-
able to accurately estimate age of diabetes
onset. As such, we were unable to precisely
characterize the effects of total disease
duration from onset in middle age on cog-
nitive decline and MCI. Nevertheless, our
findings provide new insights into the ef-
fects of midlife diabetes on cognitive aging
and impairment among diverse Latinos who
are at risk for diabetes complications.
Conclusion
Diabetes was associated with marked
7-year cognitive decline and increased MCI
prevalenceamongdiversemiddle-agedand
older Latinos but primarily among those
with diabetes at visit 1. Diabetes disease
onsettypicallyoccurs inmiddleage,andour
findings suggest that middle age is a par-
ticularly vulnerable period in lifedwhen
theeffectsofdiabetesoncognitive function
and decline begin. Ourfindings additionally
suggest that intensive public health and
clinicalmessaging targeting individuals with
early-stage diabetes might strengthen pa-
tients’motivation for adherence to diabe-
tes management and treatment efforts in
midlife and may have important implica-
tions for controlling diabetes complications,
including cognitive decline and impairment,
among diverse Latinos.
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Figure 2—Estimates of crude and adjusted
marginal probability (and their 95% CIs) of
MCI. Results are derived from survey logistic
regression models. Prevalent diabetes, since
visit 1; incident diabetes, at visit 2. Adjusted
models correct for Latino background (six
groups), sex, age, education (,12 years, 12
years, .12 years), language preference (En-
glish, Spanish),whether someone is a current
smoker (0 5 no, 1 5 yes), a dichotomous
indicator for alcohol consumption (one or
moredrinks per day), self-reported prevalent
strokeorTIA,myocardial infarction,BMIbased
on weight measured in kilograms and height
measured in centimeters, and$10 on CESD-
10. With the exception of age, all covariates
were measured at baseline.
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